奥洛兹美医疗 HALO 深 沪
已收盘 01-30 16:00:00 美东时间
71.71
-1.630
-2.22%
华盛通- 最 高74.48
- 今 开73.34
- 成交量 204.43万股
- 最 低 71.30
- 昨 收 73.34
- 总市值 83.90亿
- 52周最高 79.50
- 市盈率 静 20.90
- 换手率 1.75%
- 52周最低 47.50
- 委 比 -40.96%
- 总股本 1.17亿
- 历史最高 79.50
- 量 比 1.15
- 振 幅 4.34%
- 历史最低 3.86
- 每 手 1
- 风险率 7.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多U.S. RESEARCH ROUNDUP-AGNC Investment, Brown & Brown, Korro Bio
U.S. RESEARCH ROUNDUP-AGNC Investment, Brown & Brown, Korro Bio Jan 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AGNC Investment, Brown & Brown and Korro Bio, on Thursday. HIGHLIGHTS * AGNC Investment Corp AGNC.O :
01-29 15:54
Halozyme Therapeutics Projects Sustained Growth Well Into 2040
Halozyme raised 2026 guidance, projected royalty revenue above $1B, and outlined long-term growth following strong ENHANZE momentum and acquisitions.
01-29 02:58
Halozyme raises outlook, buys Surf Bio
Halozyme Therapeutics (HALO) shares edged 0.5% higher Wednesday morning after it raised its financial outlook and announced the acquisition of biopharmaceutical company Surf Bio for a total considerat...
01-28 20:09
Halozyme Therapeutics Acquires Surf Bio For Total Consideration Of Up To $400M
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today provided a business update, including providing preliminary unaudited 2025 revenue estimates and raising full year 2026 and multi-year
01-28 19:43
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
Updates Preliminary Unaudited 2025 Estimates: - Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1 - Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises...
01-28 19:30
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
MBX Biosciences has appointed Laurie Stelzer as an independent director and chair of the audit committee, leveraging her extensive financial and executive experience. Stelzer, with a strong background in biopharmaceutical finance, is expected to contribute to the company’s upcoming clinical data releases and Phase 3 trial in hypoparathyroidism. MBX Biosciences focuses on developing precision peptide therapies for endocrine and metabolic disorders...
01-22 13:00
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Skye Bioscience Announced Non-Exclusive License Agreement For Halozyme Therapeutics' Enhanze Drug Delivery Technology For The Development And Potential Commercialization Of A Subcutaneous Formulation Of Nimacimab For Obesity
Skye will make milestone payments tied to the achievement of certain development and commercialization events. Halozyme will also be entitled to mid-single digit royalties on net sales of nimacimab developed with ENHANZE
01-05 20:16
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Halozyme Therapeutics and Skye Bioscience have entered into a global collaboration to develop and commercialize a subcutaneous formulation of nimacimab for obesity using Halozyme's ENHANZE® technology. Skye aims to evaluate higher doses of nimacimab and plans to initiate a Phase 2b trial in 2026. Halozyme will receive milestone payments and royalties on future sales.
01-05 12:00
Halozyme Says FDA Approves Johnson & Johnson's Five-Minute Injection Version Of Lung Cancer Drug RYBREVANT
Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and
2025-12-18 20:07
